ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Interim Chief Financial Officer, James Lee, will participate at Canaccord Genuity's 44th Annual Growth Conference, taking place from August 13 to 15, 2024, at the InterContinental in Boston.

For 44 years, Canaccord Genuity's Annual Growth Conference has been a cornerstone for industry leaders and investors, fostering valuable connections and insights.

Mr. Fried and Mr. Lee will lead a presentation on Wednesday, August 14, and conduct one-on-one meetings throughout the conference to discuss ChromaDex's latest developments, strategic initiatives, and growth opportunities with investors and industry experts.

For more information about ChromaDex's participation or to arrange a meeting with Mr. Fried and Mr. Lee, please visit the conference website here, or contact your CG representative.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen is the active ingredient in ChromaDex's consumer products, sold as the brand Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^?. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com).

ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

^?Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).